MAO-B inhibition by selegiline blunts cardiac functions improved by high-fat diet: Role of inflammation, apoptosis, and calcium-handling.

Hambalkó, Szabolcs, Pelyhe, Csilla, Kovácsházi, Csenger, Kenyeres, Bence, Kiss, Bernadett, Ágg, Bence, Gergely, Tamás G, Weber, Bennet Y, Makkos, András, Brenner, Gábor B, Komlódi, Tímea, Tretter, László, Horváth, Csaba, Jarabicová, Izabela, Adameová, Adriana, Görbe, Anikó, Poggi, Paola, Chatgilialoglu, Alexandros, Horváth, Ildikó, Máthé, Domokos, Szigeti, Krisztián, Oláh, Attila, Radovits, Tamás, Varga, Zoltán V, Merkely, Béla, Baxter, Gary F ORCID: https://orcid.org/0000-0002-7887-6841, Schulz, Rainer, Ferdinandy, Péter and Giricz, Zoltán 2025. MAO-B inhibition by selegiline blunts cardiac functions improved by high-fat diet: Role of inflammation, apoptosis, and calcium-handling. Current research in pharmacology and drug discovery 9 , 100237. 10.1016/j.crphar.2025.100237

PDF Download (4MB)

Abstract

BackgroundObesity is a major risk factor for the development of cardiovascular disease. However, recent research shows that moderate obesity reduces the risk of developing cardiovascular disease. We evidenced before that MAO-B inhibitor selegiline reduced visceral adiposity.AimTherefore, our aim was to investigate cardiac effects of selegiline in moderate obesity in rats treated with a high-fat diet (HFD).Key findingsWe demonstrated that HFD improved cardiac contractility parameters, which were reversed by selegiline. Enhanced contractility might be attributed to an increased sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA2a) expression and phospholamban pentamerization. Selegiline reduced SERCA2a expression in HFD. HFD increased Tumor necrosis factor and Nuclear factor-kappa B expression which were not affected by selegiline. HFD induced proapoptotic processes, which were restored by selegiline.ConclusionIn conclusion, moderate obesity improves cardiac function through Ca2+ homeostasis and inflammatory processes and MAO-B inhibition reverses these effects.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Pharmacy
Additional Information:	License information from Publisher: LICENSE 1: Title: cc by, Type: cc by
Date of Acceptance:	6 November 2025
Last Modified:	18 Dec 2025 11:30
URI:	https://orca.cardiff.ac.uk/id/eprint/183361

Actions (repository staff only)

Edit Item